Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

The webcast and dial-in information can be accessed on the Investor page of Travere’s website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Contact Info

Media:
888-969-7879                                        
mediarelations@travere.com
Investors:
888-969-7879                                        
IR@travere.com

Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  228.74
-0.51 (-0.22%)
AAPL  268.39
-0.61 (-0.23%)
AMD  262.96
+4.95 (1.92%)
BAC  52.65
-0.22 (-0.42%)
GOOG  273.50
+5.07 (1.89%)
META  746.86
-4.59 (-0.61%)
MSFT  538.86
-3.21 (-0.59%)
NVDA  206.02
+4.99 (2.48%)
ORCL  274.06
-6.77 (-2.41%)
TSLA  460.32
-0.23 (-0.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.